Rebuilding the Body from Within, Fueled through NIH Funding
$3.3M
Non-dilutive funding awarded
Inspired by the ancient “Ship of Theseus” paradox — whether something remains the same after all its parts are replaced — Ship of Theseus was founded to enhance the body’s own ability to rebuild and restore itself. The company is developing a new class of biologics that target “master switch” regulatory proteins known as HOX transcription factors, so as to accelerate production of healthy blood cells and improve recovery for patients undergoing chemotherapy or bone marrow transplants.
To advance its vision, Ship of Theseus partnered with EGC to secure critical non-dilutive funding, resulting in more than $3.3 million in NIH awards. The 6-year partnership has encompassed grant strategy and proposal development, as well as ongoing accounting and compliance.
Ship of Theseus continues to leverage non-dilutive funding as a key part of their fundraising strategy as they advance their core technology for a wide range of indications to support patient recovery.
Listen to the Interview with Co-Founder Ed Burgard, Ph.D.
Eva Garland Consulting CEO, Dr. Eva Garland, speaks with Dignify Therapeutics co-founder Dr. Ed Burgard. Ed provides insight on how EGC has helped guide their non-dilutive funding approach, which started 10 years of consistent funding.
“My favorite part of working with EGC is how deeply the consultants embed with the technology. Beyond handling the administration and registrations, they contribute directly to the text while needing only high level direction.”
– Jeremy Elser, Ph.D., CEO, Ship of Theseus
Funding Sources
